Controlling cardiac arrhythmias: An overview with a historical perspective

American Journal of Cardiology

Volumn 80, Issue 8 A, 1997, Pages

  Singh, Bramah N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

CATHETER ABLATION; DEFIBRILLATION; DEVICE; DRUG EFFECT; HEART ARRHYTHMIA; HUMAN; IMPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; SURVIVAL;

EID: 0030810360     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00709-1     Document Type: Article

References (78)

1. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med. 312:1985;193-197.
2. Rappaport E, Remedios P. The high risk patient after recovery from myocardial infarction recognition and management . J Am Coll Cardiol. 1:1983;391-399.
3. Van Olshausen K, Schafer A, Mehmel HC. Ventricular arrhythmia in dilated cardiomyopathy. Br Heart J. 51:1984;147-152.
4. Stevensen WG, Ellison KE, Lefroy DC, Friedman PL. Ablation therapy for cardiac arrhythmias. Am J Cardiol. 80:(suppl):1997;56G-66G.
5. Johnson EA, McKinnon MG. The differential effects of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J Pharmacol Exp Therap. 120:1957;460-468.
6. Singh BN. Routine prophylactic lidocaine administration in acute myocardial infarction. An idea whose time is all but gone? Circulation. 86:1992;764-773.
7. Jervell A, Lang-Nielsen L. Congenital deaf-mutism, functional heart disease with the prolongation of QT interval, and sudden death. Am Heart J. 54:1957;59-68.
8. Selzer A, Wray HW. Quinidine syncope paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias . Circulation. 30:1964;17-26.
9. Dessertenne F. La tachycardia ventriculaire a deux foyers oppose variables. Arch Mal Coeur. 59:1966;263-272.
10. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 . Br J Pharmacol. 39:1970;675-687.
11. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 39:1970;657-667.
12. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flenstedt-Jensen E, Olesen KH, eds. Symposium on Cardiac Arrhythmias. Sweden: AB Astra, Sodertalje, 1970:440-469.
13. Singh BN. Pharmacological actions of certain cardiac drugs and hormones: focus on antiarrhythmic mechanisms. (Thesis.) Hertford College and the University of Oxford; 1971. Mount Kisco, NY: Futura Publishing, 1991:1-98.
14. Singh BN, Vaughan Williams EM. Effects of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res. 29:1971;286-295.
15. Singh BN, Vaughan Williams EM. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res. 39:1972;109-119.
16. Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 87:1974;367-377.
17. The Sicilian Gambit a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms . Circulation. 84:1991;1831-1851.
18. Singh BN. The coming of age of the class III antiarrhythmic principle retrospective and future trends . Am J Cardiol. 78:(suppl 4A):1996;17-27.
19. Yusuf S, Teo KK. Approaches to prevention of sudden death need for fundamental reevaluation . J Cardiovasc Electrophysiol. 2:1991;S233-S239.
20. Singh BN. Arrhythmia control by prolonging repolarization the concept and its potential therapeutic impact . Eur Heart J. 14:1993;14-23.
21. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction . N Engl J Med. 321:1989;1754-1756.
22. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
23. Ahmed R, Singh BN. Anti-arrhythmic drugs. Curr Opin Cardiol. 8:1993;10-21.
24. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol. 9:1994;12-22.
25. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 68:1991;1025-1031.
26. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 82:1990;1106-1116.
27. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 20:1992;427-532.
28. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis. Circulation. 84:1991;1977-1983.
29. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;452-458.
30. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med. 329:1993;445-451.
31. Randomized anti-arrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. 72:1993;280-287.
32. Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, Wiesfeld AC, Bakker PF, Robles de Medina EO. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in post-infarct sudden death survivors. Circulation. 91:1995;2195-2203.
33. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation. 82:1990;2235-2242.
34. Singh BN. Expanding indications for the use of class III agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol. 6:1995;887-900.
35. Singh BN. Control of cardiac arrhythmias with sotalol, a broad-spectrum anti-arrhythmic with beta-blocking effects and class III activity. Am J Cardiol. 765:1990;1A-84A.
36. Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1:1982;1142-1147.
37. Hohnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects a review with special reference to torsades de pointes tachycardia . Ann Intern Med. 121:1994;529-535.
38. Singh BN. Choice and chance in drug therapy of cardiac arrhythmias technique versus drug-specific responses in evaluation of efficacy . Am J Cardiol. 72:1993;114-124.
39. Ho DS, Zecchin RP, Richards DA, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 344:1994;18-23.
40. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 82:1990;1932-1939.
41. + Channels in Cardiovascular Medicine. Paris: Springer-Verlag, 1993:247-262.
42. Feld GK, Venkatesh N, Singh BN. Pharmacologic conversion and suppression of experimental canine flutter differing effects of d-sotalol, quinidine and lidocaine and significance of changes in refractoriness and conduction . Circulation. 74:1985;197-204.
43. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vander Lugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621.
44. Falk RH, Pollak A, Singh SN, Friederich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 29:1997;385-390.
45. Roden DM. Ibutilide and the treatment of atrial arrhythmias. A new drug - almost unheralded - is now available to US physicians. Circulation. 94:1996;1499-1502.
46. Singh BN. Acute conversion of atrial fibrillation and flutter direct current cardioversion versus intravenously administered pure class III agents . (Editorial.) J Am Coll Cardiol. 29:1997;391-393.
47. Singh BN, Wellens HJ, Hiraoka M. Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness? 1994;1-713 Futura Publishing, Mount Kisco, NY.
48. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of cardiac repolarization theoretical considerations and clinical observations . Am Heart J. 109:1985;421-430.
49. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 348:1996;7-12.
50. Papp J, Gy Nemeth M, Krassoi I, Mester L, Hala O, Varro A. Differential electro-physiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Therap. 1:1996;187-196.
51. Sicouri S, Moro S, Litovsky S, Elizari M, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 1997; in press.
52. Cui G, Sen L, Sager P, Uppal P, Singh BN. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol. 74:1994;896-900.
53. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 88:1993;1063-1071.
54. Takanaka C, Singh BN. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations significance of slow channel activity and differing effects of quinidine and amiodarone . J Am Coll Cardiol. 15:1990;213-221.
55. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation. 92:1995;3255-3263.
56. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation. 92:1995;3264-3272.
57. Nasir N, Swarna U, Bolhene KA, Doyle TK, Pacifico A. Therapy of sustained ventricular arrhythmias with amiodarone prediction of efficacy with serial electrophysiologic studies . J Cardiovasc Pharmacol Therapeut. 1:1996;123-132.
58. Hennekins CH, Godfried SL, Albert CM, Gaziano JM, Buring JE. Adjunctive drug therapies during and post acute myocardial infarction. N Engl J Med. 335:1996;1660-1667.
59. Yusuf S, Peto R, Lewis J, Sleight P. Beta-blockade during myocardial infarction an overview of randomized trials . Prog Cardiovasc Dis. 27:1985;335-355.
60. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:1986;503-510.
61. Singh BN. Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction. Am J Cardiol. 66:1990;9C-20C.
62. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone and post-MI patients. Circulation. 88:1993;764-774.
63. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-674.
64. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations CAMIAT . Lancet. 349:1997;675-682.
65. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
66. Singh SN, Fletcher RD, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med. 333:1995;77-82.
67. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
68. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Newberg GW, Frid D, Wertheimer JH, Cropp AB, De Mets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Eng J Med. 335:1996;1107-1114.
69. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 90:1994;1765-1773.
70. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, Le Jemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation. 94:1996;2793-2799.
71. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
72. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
73. Haverkamp W, Eckardt L, Boggrefe M, Breithardt G. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. Am J Cardiol. 80:(suppl):1997;67G-73G.
74. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 335:1996;1933-1940.
75. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation. 82:1990;350-358.
76. Ogunyankin K, Singh BN. Editorial Reflections on some recent and contemporary clinical trials in patients with heart failure and those with reduced ventricular function . J Cardiovasc Pharmacol Therapeut. 2:1997;147-152.
77. Hallstrom A, Zipes DP. Preliminary findings of the Antiarrhythmic Versus Implantable Device Trial (AVID). Presentation at the Annual Scientific Meeting of the North American Society of Pacing and Electrophysiology, New Orleans, May 12, 1996.
78. Singh BN. Amiodarone the expanding antiarrhythmic role and how to follow a patient on chronic therapy . Clin Cardiol. 20:1997;608-618.